Literature DB >> 2176542

Malignant fibrous histiocytomas with a 19p+ marker chromosome have increased relapse rate.

A Rydholm1, N Mandahl, S Heim, A Kreicbergs, H Willén, F Mitelman.   

Abstract

Malignant fibrous histiocytomas (MFH) often have complex karyotypic abnormalities. Recently, we described a 19p+ marker chromosome in 9 of 22 MFH. Other recurrent karyotypic features have been telomeric associations, ring chromosomes, and structural rearrangements of chromosomal bands 1q11, 3p12, and 11p11. After a median follow-up time of 18 months, distant metastases and/or local recurrence have occurred in 8 of the 9 patients with 19p+ markers but in only 4 of the 13 patients without. The only other cytogenetic parameter that seemed to affect relapse tendency was the presence of ring markers: relapse has occurred in 2 of 8 patients with unidentifiable supernumerary ring marker chromosomes compared to 10 of 14 patients without. No differences in relapse frequency were apparent for tumors belonging to the other cytogenetic subgroups. It thus appears that 19p+ marker chromosomes in MFH signal an increased relapse risk whereas the finding of ring markers indicates a reduced relapse risk.

Entities:  

Mesh:

Year:  1990        PMID: 2176542     DOI: 10.1002/gcc.2870020407

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

1.  Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker.

Authors:  M L Larramendy; M Tarkkanen; C Blomqvist; M Virolainen; T Wiklund; S Asko-Seljavaara; I Elomaa; S Knuutila
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Proposal for Modification of Cahan's Criteria Utilizing Molecular Genetic Analyses for Cases without Baseline Histopathology: A Unique Method Applicable to Primary Radiosurgery.

Authors:  Aaron E Rusheen; James B Smadbeck; Lisa A Schimmenti; Eric W Klee; Michael J Link; George Vasmatzis; Matthew L Carlson
Journal:  J Neurol Surg B Skull Base       Date:  2018-05-31

Review 3.  Diagnostic and prognostic implications of the unfolding molecular biology of bone and soft tissue tumours.

Authors:  J F Graadt van Roggen; J V Bovée; J Morreau; P C Hogendoorn
Journal:  J Clin Pathol       Date:  1999-07       Impact factor: 3.411

Review 4.  Chromosomal aberrations in soft tissue tumors. Relevance to diagnosis, classification, and molecular mechanisms.

Authors:  C Sreekantaiah; M Ladanyi; E Rodriguez; R S Chaganti
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

5.  Establishment of a new human pleomorphic malignant fibrous histiocytoma cell line, FU-MFH-2: molecular cytogenetic characterization by multicolor fluorescence in situ hybridization and comparative genomic hybridization.

Authors:  Jun Nishio; Hiroshi Iwasaki; Kazuki Nabeshima; Masako Ishiguro; Teruto Isayama; Masatoshi Naito
Journal:  J Exp Clin Cancer Res       Date:  2010-11-24

6.  Cytogenetic evolution in primary tumors, local recurrences, and pulmonary metastases of two soft tissue sarcomas.

Authors:  C Orndal; N Mandahl; H Willén; A Rydholm; F Mitelman
Journal:  Clin Exp Metastasis       Date:  1993-09       Impact factor: 5.150

7.  Prognostic impact of chromosome aberrations in ovarian cancer.

Authors:  T Pejovic; A Himmelmann; S Heim; N Mandahl; U M Flodérus; S Furgyik; B Elmfors; G Helm; H Willén; F Mitelman
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

8.  Gain of 17q in malignant fibrous histiocytoma is associated with a longer disease-free survival and a low risk of developing distant metastasis.

Authors:  W-H Weng; J Ahlén; W-O Lui; O Brosjö; S-T Pang; A Von Rosen; G Auer; O Larsson; C Larsson
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

9.  Myxoid malignant fibrous histiocytoma with multiple primary sites.

Authors:  Jeffrey H Muler; Augusto F Paulino; Diane Roulston; Laurence H Baker
Journal:  Sarcoma       Date:  2002
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.